Faruqi & Faruqi, LLP Is Seeking More Cash For The Shareholders Of DUSA Pharmaceuticals, Inc. (DUSA)
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of DUSA Pharmaceuticals, Inc. (“DUSA” or the “Company”) (NASDAQ: DUSA) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) in an all-cash deal valued at approximately $230 million. Under the terms of the proposed transaction, DUSA’s stockholders will receive $8 in cash for each share of DUSA common stock they own, while according to Yahoo! Finance, at least one financial analyst has set a price target of $9.50 for DUSA.
The investigation focuses on whether DUSA’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of DUSA’s shareholders.
If you own common stock in DUSA and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.